First Turn Management LLC Invests $19.76 Million in Natera, Inc. (NASDAQ:NTRA)

First Turn Management LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 155,650 shares of the medical research company’s stock, valued at approximately $19,760,000. Natera accounts for 3.1% of First Turn Management LLC’s holdings, making the stock its 9th biggest position. First Turn Management LLC owned approximately 0.13% of Natera as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. purchased a new stake in Natera in the second quarter valued at approximately $28,000. Quarry LP boosted its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. Covestor Ltd lifted its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. Finally, Tobam purchased a new position in Natera during the second quarter valued at $74,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NTRA shares. Robert W. Baird boosted their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partners upped their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Craig Hallum upped their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Finally, UBS Group decreased their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $140.59.

Natera Stock Up 5.0 %

NASDAQ:NTRA opened at $153.42 on Tuesday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average of $127.38 and a 200-day moving average of $115.76. Natera, Inc. has a 52 week low of $53.31 and a 52 week high of $167.79.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) earnings per share. Sell-side analysts expect that Natera, Inc. will post -1.7 EPS for the current year.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the completion of the sale, the chief executive officer now owns 185,034 shares in the company, valued at approximately $27,090,827.94. This trade represents a 2.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 256 shares of the stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the transaction, the insider now directly owns 111,891 shares of the company’s stock, valued at $13,434,752.37. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,821 shares of company stock worth $4,776,878. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.